Welcome to our dedicated page for BIOVAXYS TECHNOLOGY news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BIOVAXYS TECHNOLOGY stock.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform. They focus on treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company has a range of products in their clinical stage pipeline, including maveropepimut-S and BVX-0918, which target different types of cancers like Diffuse Large B Cell Lymphoma (DLBCL) and ovarian cancer. BioVaxys also capitalizes on its tumor immunology expertise to identify new targetable tumor antigens using predictive algorithms and other technologies.
BioVaxys Technology Corp (BVAXF) is developing its DPX™ platform as an alternative to lipid nanoparticles (LNPs) for delivering mRNA vaccines. The DPX technology is a patented delivery platform that can incorporate various bioactive molecules to produce targeted, long-lasting immune responses.
Proof-of-concept studies conducted with Etherna and PCI Biotech showed that DPX provides enhanced stability of packaged mRNA, attracts specific Antigen Presenting Cells to the injection site, and induces specific immune responses. Unlike LNPs, which can cause adverse reactions and stability issues, DPX remains localized at the injection site and demonstrated stability for up to 14 days in vivo.
The company is pursuing collaborations with organizations having promising tumor and virus-specific polynucleotide antigens, positioning DPX as a potential solution in the mRNA vaccine market, which is projected to reach $48 billion by 2030.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has announced its upcoming presentation at the Emerging Growth Conference on Thursday, January 16, 2025, from 3:25 PM to 3:35 PM Eastern Time. The clinical-stage company, which develops vaccines using its DPX™ immune educating platform for cancers, infectious diseases, and immune disorders, will host an interactive online session.
CEO James Passin and President & COO Kenneth Kovan will lead the presentation, offering shareholders and investors a real-time interaction opportunity. The event includes a Q&A session, with questions accepted both in advance via Questions@EmergingGrowth.com and during the live presentation. Participants who cannot attend live can access an archived webcast through EmergingGrowth.com and their YouTube channel.
BioVaxys Technology Corp (CSE: BIOV, OTCQB: BVAXF) has secured a 48-kilogram supply of GMP-grade lipid for its DPX antigen packaging delivery platform. The lipids, previously owned by IMV Inc., will be used to restart clinical studies and initiate new preclinical studies. The company acquired IMV's intellectual property and programs in February 2024.
The DPX technology is a patented delivery platform capable of packaging various bioactive molecules, including mRNA, peptides, proteins, and small molecules. This non-aqueous and non-systemic platform enables immune cell recruitment and antigen uptake at injection sites, delivering to regional lymph nodes via Antigen Presenting Cells to stimulate durable immune responses.
BioVaxys Technology Corp. and SpayVac for Wildlife announce that SpayVac's Madison facility is now fully operational to produce two contraceptive vaccines: the pZP vaccine (SpayVac®) and a new GnRH vaccine for aquaculture. The scaled-up production capacity will support field trials, market studies, and new antigen formulations. Recent large-scale shipments were made for a feral horse project in Europe and an immunocontraception project in Southeast Asia. The company is conducting trials with the U.S. government, EU, and an aquaculture genetics company, exploring alternatives to induced triploidy. SpayVac's technology, licensed from BioVaxys, uses a patented liposome-based antigen delivery platform.
BioVaxys Technology Corp (OTCQB: BVAXF) has joined the Rapid Response Partnership Vehicle (RRPV), a consortium supporting the US Government's Biomedical Advanced Research and Development Authority (BARDA). The RRPV aims to accelerate medical countermeasure development for pandemic influenza, emerging infectious diseases, and biological threats. The consortium includes major organizations like AstraZeneca, Novavax, and Genentech. BioVaxys believes its DPX platform can significantly contribute to BARDA's vaccine programs. The company's clinical pipeline includes maveropepimut-S, currently in Phase II trials for lymphoma and ovarian cancer treatment.
BioVaxys Technology Corp (OTCQB: BVAXF) has announced significant study results for its DPX™ immune-educating delivery platform. The research, conducted with Dalhousie University, demonstrates that DPX outperforms traditional aqueous and emulsion-based antigen delivery systems in immune system activation. Key findings show that DPX maintains antigens at the injection site and drives active APC uptake over time. The platform demonstrated superior lymphocyte retention and significant immune cell infiltration within 2 days of injection. Notably, DPX showed activation of more critical T cell subset markers than oil emulsion systems and exhibited inherent immune-activating properties even without antigen cargo.
BioVaxys Technology Corp (CSE: BIOV, OTCQB: BVAXF) announces its participation in the upcoming Emerging Growth Conference on October 30th, 2024, at 9:40 AM EST. CEO James Passin will deliver a live, interactive presentation, providing an opportunity for shareholders and investors to engage directly with the company leadership.
The clinical-stage company, which develops immune-educating therapies using its DPX™ platform for cancers, infectious diseases, and immune disorders, welcomes questions from participants either in advance via Questions@EmergingGrowth.com or during the live event. For those unable to attend, an archived webcast will be available on EmergingGrowth.com and their YouTube channel.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has engaged Dr. Rajkannan Rajagopalan as Advisor for developing and producing the Company's DPX™ formulations. Dr. Rajagopalan, with over 20 years of experience in nanoparticles formulation development, will assist with:
- Development of DPX formulations for the peanut allergy vaccine program with McMaster University
- Planned preclinical studies of DPX/mRNA vaccines
- Continued Phase 1 studies in oncology and infectious disease
- Expansion into new opportunities with DPX
- Support for current licensees using liposomes-based vaccine technology
- Establishing BioVaxys' non-GLP clinical supply facility for DPX formulations production
Additionally, Brittany Davison, a Chartered Professional Accountant, joins as an Advisor from the former IMV, Inc., where she served as Chief Accounting Officer and Acting Chief Financial Officer.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) announces CEO James Passin's upcoming presentation at the Life Sciences Investor Forum on September 19th, 2024. The live, interactive online event allows investors to engage directly with the company.
Recent highlights include:
- Acquisition of DPX™ immune educating platform technology assets
- Collaboration with AP Visionaries to develop food allergy treatments
- Potential product registrations from licensees Zoetis and SpayVac-for-Wildlife
- Advancement of DPX™ platform for infectious diseases
BioVaxys is developing novel immunotherapies for cancers, infectious diseases, and other immunological conditions using its DPX™ and HapTenix© platforms. The company's lead candidate, maveropepimut-S, is in Phase II trials for DLBCL and ovarian cancer.
BioVaxys Technology Corp. (BVAXF) has been invited to present at The Personalized Cancer Vaccine Summit in Boston, MA, from December 3-5, 2024. The presentation, titled "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies," will showcase new data on the company's DPX Immune Educating Platform.
Chief Medical Officer David Berd, MD, will present findings from recent in vivo studies conducted by researchers at UConn Health and The Ohio State University Comprehensive Cancer Center. The data suggests that DPX has a significant role in delivering tumor neoepitope vaccines that induce tumor rejection and may possess anti-tumor capacity on its own.
BioVaxys is continuing additional studies on DPX's potential in delivering tumor neoepitope vaccines and its anti-tumor capabilities.
FAQ
What is the current stock price of BIOVAXYS TECHNOLOGY (BVAXF)?
What is the market cap of BIOVAXYS TECHNOLOGY (BVAXF)?
What is BioVaxys Technology Corp focused on?
What are some products in BioVaxys' clinical stage pipeline?
How does BioVaxys identify new targetable tumor antigens?
